资讯

New York-based biotech giant Regeneron Pharmaceuticals announced May 19 its plan to purchase the bankrupt genetic testing firm 23andMe in a $256 million deal that could include millions of ...
Regeneron acquires 23andMe for $256M following bankruptcy auction Regeneron will take over key assets including 23andMe’s Personal Genome Service, Biobank, Total Health, and research operations, ...
23andMe has found itself a buyer after biotech Regeneron won an auction to buy the bankrupt genetics company for $256m. As part of a court-supervised sale, the auction will see Regeneron acquire ...
Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million people, to the drug developer Regeneron Pharmaceuticals for $256 million.
Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness ...
Regeneron is acquiring “substantially all” of 23andMe’s assets for $256 million following a bankruptcy auction.
Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.
Regeneron Pharmaceuticals said it will acquire 23andMe's business. What happened to 23andMe? Should you delete your data? What to know.
Purchase is subject to bankruptcy court and regulatory approvals Regeneron will prioritize the privacy, security and ethical use of 23andMe’s customer data; stands ready to work with independent ...